about BIOSOLUTION

Our company was established with the purpose of developing, manufacturing and selling cell therapy products. We have developed a human tissue model and an alternative test method through the application of our proprietary cell therapy development technology, and attained international certification of the model (listed in the OECD TG on April 2019). We seek to not only to make our technology known, but also preemptively react to future market trends to ensure constant growth and development moving forward.

Our company’s commercialization and market acquisition of advanced biopharmaceuticals including cell therapy products is directly connected to the company’s growth potential. Cellular therapies are much more advantageous in clinical trials and market entry, which is reinforced by the fact that autologous keratinocyte cell therapy and chondrocyte cell therapies are marketable after completion of Phase 2 Clinical Trials. Moving forward, we will focus on the development of autologous treatments such as KeraHeal, KeraHeal-Allo, CartiLife and CartilOiD, then on their allogenic variants in order to attain both speed and accessibility in commercialization.

Business plan and Strategy

As we step into the 21st century, the average human lifespan has become increasingly lengthy with the introduction of widespread healthcare and medical benefits. Degenerative diseases, genetic abnormalities, disabilities, accidents and diseases have led to the advent of tissue engineering and regenerative medicine as a branch of medicine, and the demand for novel pharmaceutics capable of improving the functional capability of cells or tissues through treatments targeting the fundamental issue have reached new levels of desirability. Biosolution Co., Ltd is focused on the development and marketing of cell-based therapy products with high innate market performance and utility value. We have developed numerous product lines with our proprietary cell manipulation technologies, and through its application to many different types of cells, aim to attain relevance and advantage in the ever-changing market with improved, innovative next-generation treatments. We aimed to use the cornerstone built from our expertise in cell-based therapies towards building a future driving force for human tissue models augmented with cell manipulation technologies, and focus on expanding our market within South Korea and beyond by taking the first step forward with our registration of OECD international test guideline for our tissue model. Biosolution Co., Ltd aims to contribute to the happiness and well-being of humanity as a global leader of biotechnology and cell-based technology.